1 m 2 Patients must have a diagnosis of neuroblastoma based upon tumor histology or bone marrow metastases and elevated urine catecholamine metabolites. The APC criteria include counts obtained while on G-CSF therapy. Veno-occlusive disease, if present, should be stable or improving. Patients must have a double lumen catheter or single lumen and peripheral IV so that IL-2 and ch14.18 can be given separately. Patients who were previously treated with antibody 14.G2a or ch14.18 are ineligible for this study.
Patients requiring chronic use of corticosteroids are ineligible.
Corticosteroid, immunosuppressive drugs, myelosuppressive chemotherapy, and retinoic acid must not be given within 14 days prior to study entry. Radiation therapy must not be given within seven days prior to study entry or during therapy. All institutional, FDA, and NCI requirements for human studies must be met. Copyright 1995 - 2000 National Childhood Cancer Foundation. All rights reserved.